Breaking: Carvana Boosts Outlook; Bullish View On RAPT Therapeutics
- August 09th, 2023
- 477 views
Shares of Carvana Co. (NYSE: CVNA) surged over 5% in pre-market trading following its announcement of an enhanced Q3 2023 outlook. The improvement is attributed to significant advancements in key business drivers and strong early-quarter momentum.
Specifically, Carvana has raised its Q3 adjusted EBITDA view to exceed $75 million, marking a shift from positive adjusted EBITDA.
$CVNA was trading at $47.50 in pre-market, reflecting a substantial increase of $3.49 (+7.93%).
In other news, RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company, received positive attention from Stifel as the investment banking firm initiated coverage with a Buy rating and a price target of $40.
Closing at $22.58 on Tuesday, this suggests a potential upside of $17.42 or approximately 77.03% for $RAPT, according to Stifel's assessment.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login